Terms: = Breast cancer AND KMT2C, ENSG00000055609, MLL3, 58508 AND Prognosis
11 results:
1. Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract] [Full Text] [Related]
2. Deciphering Brain Metastasis Stem Cell Properties From Colorectal cancer Highlights Specific Stemness Signature and Shared Molecular Features.
Desette A; Guichet PO; Emambux S; Masliantsev K; Cortes U; Ndiaye B; Milin S; George S; Faigner M; Tisserand J; Gaillard A; Brot S; Wager M; Tougeron D; Karayan-Tapon L
Cell Mol Gastroenterol Hepatol; 2023; 16(5):757-782. PubMed ID: 37482243
[TBL] [Abstract] [Full Text] [Related]
3. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH; Im SA; Park K; Wen J; Lee KH; Choi YL; Lee WC; Min A; Bonato V; Park S; Ram S; Lee DW; Kim JY; Lee SK; Lee WW; Lee J; Kim M; Kim HS; Weinrich SL; Ryu HS; Kim TY; Dann S; Kim YJ; Fernandez DR; Koh J; Wang S; Park SY; Deng S; Powell E; Ravi RK; Bienkowska J; Rejto PA; Park WY; Kan Z
Genome Med; 2023 Jul; 15(1):55. PubMed ID: 37475004
[TBL] [Abstract] [Full Text] [Related]
4. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in breast cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive Analysis of Metabolic Genes in breast cancer Based on Multi-Omics Data.
Hua Y; Gao L; Li X
Pathol Oncol Res; 2021; 27():1609789. PubMed ID: 34408553
[No Abstract] [Full Text] [Related]
6. kmt2c is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer.
Liu X; Qiu R; Xu M; Meng M; Zhao S; Ji J; Yang Y
Breast Cancer Res Treat; 2021 Sep; 189(2):347-361. PubMed ID: 34240274
[TBL] [Abstract] [Full Text] [Related]
7. Association between histone lysine methyltransferase kmt2c mutation and clinicopathological factors in breast cancer.
Chen X; Zhang G; Chen B; Wang Y; Guo L; Cao L; Ren C; Wen L; Liao N
Biomed Pharmacother; 2019 Aug; 116():108997. PubMed ID: 31146111
[TBL] [Abstract] [Full Text] [Related]
8. Revealing clonality and subclonality of driver genes for clinical survival benefits in breast cancer.
Lan Y; Zhao E; Luo S; Xiao Y; Li X; Cheng S
Breast Cancer Res Treat; 2019 May; 175(1):91-104. PubMed ID: 30739230
[TBL] [Abstract] [Full Text] [Related]
9. Expression Levels of kmt2c and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive breast cancer.
Sato K; Akimoto K
Clin Breast Cancer; 2017 Jun; 17(3):e135-e142. PubMed ID: 27986439
[TBL] [Abstract] [Full Text] [Related]
10. Analysis of Paired Primary-Metastatic Hormone-Receptor Positive breast Tumors (HRPBC) Uncovers Potential Novel Drivers of Hormonal Resistance.
Manso L; Mourón S; Tress M; Gómez-López G; Morente M; Ciruelos E; Rubio-Camarillo M; Rodriguez-Peralto JL; Pujana MA; Pisano DG; Quintela-Fandino M
PLoS One; 2016; 11(5):e0155840. PubMed ID: 27195705
[TBL] [Abstract] [Full Text] [Related]
11. Uterine adenosarcomas are mesenchymal neoplasms.
Piscuoglio S; Burke KA; Ng CK; Papanastasiou AD; Geyer FC; Macedo GS; Martelotto LG; de Bruijn I; De Filippo MR; Schultheis AM; Ioris RA; Levine DA; Soslow RA; Rubin BP; Reis-Filho JS; Weigelt B
J Pathol; 2016 Feb; 238(3):381-8. PubMed ID: 26592504
[TBL] [Abstract] [Full Text] [Related]
